Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on expanded insurer coverage for new drug Yeztugo.
Appeals court overturns contempt ruling against Trump officials over Venezuelan deportations, highlighting tensions between executive and judicial branches.
Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on expanded insurer coverage for new drug Yeztugo.
Appeals court overturns contempt ruling against Trump officials over Venezuelan deportations, highlighting tensions between executive and judicial branches.